SINGAPORE, March 26, 2013 /PRNewswire/ -- VolitionRx Limited (OTC: VNRX), a life sciences company focused on developing blood-based diagnostic tests, announces that it has hired Jason Terrell MD as Head of US Operations. Dr Terrell will initially be responsible for facilitating Volition's entry into the US market, acting as the company's FDA liaison and pursuing and negotiating FDA compliant US clinical trials.
Dr Terrell has a strong grounding in both medicine and more specifically in diagnostics. He currently owns and operates a number of diagnostic laboratories in Texas within the Any Lab Test Now franchise, a direct access lab testing company, and has also served as a National Franchise Corporate Medical Director for Any Lab Test Now, giving him oversight of over 70 franchises in 14 states.
Dr Terrell was educated at Hardin-Simmons University then University of Texas at Houston Medical School and affiliate MD Anderson Cancer Center. He undertook his General Medicine Internship and Anatomic and Clinical Pathology Residency at Texas Tech University Health Sciences Center. Dr Terrell holds medical licences in 14 states across the USA.
VolitionRx CEO Cameron Reynolds said: "It is extremely important for us to have a strong focus on the United States as the world's largest, and the single most important, healthcare market. We could not be happier that Dr Terrell has agreed to join Volition. He has significant experience both as a doctor and in senior roles within several healthcare diagnostic businesses, giving him a unique insight into both the medical and business perspectives."
Jason Terrell MD, said: "VolitionRx has great potential, and its technology promises to revolutionize cancer diagnostics and save countless lives. The science and management team have done a truly remarkable job, and I look forward to helping them move towards FDA approval and US rollout of their blood tests for a range of cancers."
VolitionRx is a life sciences company whose goal is to make its non-invasive blood tests for cancer as common and simple to use as existing diabetic and cholesterol tests on similar formats.
VolitionRx's development activities are currently centered in Belgium with a focus on bringing its revolutionary diagnostic products to market first in Europe, then the U.S. and worldwide.
You can find more information about VolitionRx at our website at www.volitionrx.com, on Twitter at http://www.twitter.com/VolitionRx, LinkedIn at www.linkedin.com/company/1364072?trk=tyah or Facebook at www.facebook.com/volitionrx.
Safe Harbor Statement
Statements in this press release may be "forward-looking statements". Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "optimizing," "potential," "goal," and similar expressions, as they relate to the Company, its business or management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the Company's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above and those risks discussed from time to time in the Company's filings with the Securities and Exchange Commission.
SOURCE VolitionRx Limited
Released March 26, 2013